Clinical trial
Safety Study of phIL-12-005/PPC to Treat Recurrent Ovarian Cancer
NCT00137865 · EGEN, Inc., Industry · Terminated
Key facts
| NCT number | NCT00137865 |
|---|---|
| Title | Safety Study of phIL-12-005/PPC to Treat Recurrent Ovarian Cancer |
| Official title | A Phase 1, Open Label, Dose Escalation Study of the Safety, Tolerability and Preliminary Efficacy of Intraperitoneal EGEN-001 in Patients With Recurrent Epithelial Ovarian Cancer |
| Lead sponsor | EGEN, Inc., Industry |
| Status | Terminated |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Ovarian Neoplasms |
| Intervention type | Genetic |
| Interventions | EGEN-001 (phIL-12-005/PPC) |
| Enrollment | 18 |
| Start date | Aug 1, 2005 |
| Primary completion | Oct 1, 2006 |
| Completion | Oct 1, 2006 |
| First posted | Aug 30, 2005 |
| Last update posted | Feb 28, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: